Abstract:
The present application relates to compounds of the fornula (VII), wherein the substituents R -R , X and Y are as defined in the description and to compounds of formula (VIII) or formula (IX) and when R is in the ortho position to X, R and R are taken together with the atoms to which are each attached to form an aromatic heterocyclic ring. The application further relates to polypeptides which comprise the ligand binding domain of Cdc25, crystalline forms of these polypeptides and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Cdc25. The invention also relates to the use of the three dimensional structure of the Cdc25 catalytic domain in methods of designing and/or identifying potential inhibitors of Cdc25 activity, for example, compounds which inhibit the binding of a native substrate to the Cdc25 catalytic domain.
Abstract:
The present invention relates to polypeptides which comprise the ligand binding domain of Cdc25, crystalline forms of these polypeptides and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Cdc25. The invention also relates to the use of the three dimensional structure of the Cdc25 catalytic domain in methods of designing and/or identifying potential inhibitors of Cdc25 activity, for example, compounds which inhibit the binding of a native substrate to the Cdc25 catalytic domain.
Abstract:
Peptides derived from TNF, of formula (I): X-A-Gly-Asp-Y, in which A X and Y have the meanings given in the description. Process for producing them. The novel peptides are useful therapeutic agents.
Abstract:
- 25 - O.Z. 0050/40432 of the disclosure: TNF polypeptides which differ from natural TNF by the replacement and/or deletion of amino acids are described. The novel polypeptides are suitable for controlling diseases.
Abstract:
The present invention relates to compounds that are inhibitors of interleukin-1 beta converting enzyme that have formula (I). This invention also relates to a method of treatment of stroke, inflammatory diseases, reperfusion injury, Alzheimer's disease, and shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1 beta converting enzyme.
Abstract:
- 33 - O. Z . 0050/40383 Peptides of the formula X-A-Asn-B-Y, where A, B, X and Y are defined in the description, and the preparation thereof are described. The novel peptides are suitable for controlling diseases.
Abstract:
Peptides of the formula X-A-Gly-B-Y, where A, B, X and Y are defined in the description, and the preparation thereof are described. The novel peptides are suitable for controlling diseases.
Abstract:
The sulphonamido pentanoic acid derivative or a pharmaceutically acceptable salt, amide, ester or prodrug thereof has the formula I wherein: R1 is a group of formula II; R3 is H, alkyl, -(CH2)n aryl or -(CH2)n heteroaryl; R4, R5, R6 and R7 are independently alkyl, -(CH2)n aryl or -(CH2)n heteroaryl; each n is 0 to 6; each m is 0 to 3; A is alanine, leucine, isoleucine, proline, phenylalanine, glycine, tyrosine, serine, threonine, tryptophan, cysteine, methionine, valine, asparagine, glutamine, aspartic acid, lysine, glutamic acid, arginine, or histidine; R2 is -(CH2)n-Z; Z is alkyl or optionally substituted aryl, heteroaryl, cycloalkyl or fluorenyl or a group of formula III and each RQ is independently H or alkyl. A pharmaceutical composition thereof is used for inhibiting interleukin-1b converting enzyme, inhibiting caspase-4, treating or preventing a stroke or a treating inflammatory disease.
Abstract:
Compounds of formula (I), (II) and (III) are inhibitors of interleukin-1'beta' converting enzyme. The compounds can be used in a medicament to treat stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease and shigellosis. In formula (I), (II) and (III); R1 is hydrogen, C1-C6alkyl, or benzyl; R2 is -CHO, -CORa, or -CN, Ra is independently hydrogen or C1-C6aIkyl; X is a bond, CH2, CHR5, NH, NR5, or O; R5 is hydrogen, C1-C6alkyl, aryl, or -(CH2)naryl (each n is independently 0 to 5); m is 1 or 2. In formula (I) R3 is optionally substituted-aryl, optionally substituted-heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocycle; R4 is absent, optionally substituted-aryl, C1-C8alkyl, optionally substituted heteroaryl, C1-C6alkyl, optionally substituted-cycloalkyl or optionally substituted heterocycloalkyl; Y is absent, NR5, CO, S, O, SO2, O(CHR5)n-, CHR5, NR5CO, CONR5, OCHR5, CHR5O, SCHR5, CHR5S, SO2NR5, C1-C6alkyl, NR5SO2, CH2CHR5, CHR5CH2, COCH2, or CH2CO. In formula (II); Each Z is independently hydrogen, an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or an optionally substituted heterocycle group that is fused to the phenyl group that contains Z as a substituent; Y is a bond, NR5, CO, S, O, SO2, CHR5, NR5CO, CONR5, OCHR5, -O(CHR5)n-, CHR5O, SCHR5, CHR5S, SO2NR5, NR5S02, CH2CHR5, CHR5CH2, COCH2, or CH2CO; Rb, Rc, Rd, and Re are each independently hydrogen, C1-C6alkyl, C1-C6alkoxy, -OH, C1-C6thioalkoxy, halogen, trifluoromethyl, dialkylamino, -NO2, -CN, -CF3, -CO2alkyl, -SO3H, -CHO, -COalkyl, -CONH-alkyl, -CONHRq, -CON(alkyl)2, -(CH2)n-NH2, -(CH2)n-NH-alkyl, -NHRq, -NHCORq, -(CH2)nOH, -(CH2)nCONH2, or (CH2)nCO2H, (wherein Rq is hydrogen or C1-C6alkyl). In Formula (III): Each Z is absent or independently hydrogen, an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or an optionally substituted heterocycle group that is fused to the phenyl group that contains Z as a substituent; and Rf, Rg, are each independently hydrogen, C1 -C6alkyl, hydroxy, halogen, trifluoromethyl, dialkylamino, -NO2, -CN, -CO2H, -C02alkyl, -S03H, -CHO, -COalkyl, -CONH2, -CONH(CH2)naryl, -CONH(CH2)n-substituted-aryl, -CONH-alkyl, -CONHRq, -CON(alkyl)2, -(CH2)n-NH2, -(CH2)n-NH-alkyl, -NHRq, -NHCORq, -OR9, -SR9, or -(CH2)naryl, (wherein Rq is hydrogen or C1-C6alkyl).
Abstract:
The present invention relates to compounds that are inhibitors of interleukin-1 beta converting enzyme that have formula (I). This invention also relates to a method of treatment of stroke, inflammatory diseases, reperfusion injury, Alzheimer's disease, and shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1 beta converting enzyme.